Format

Send to

Choose Destination
Cancer. 2014 Jul 1;120(13):2006-15. doi: 10.1002/cncr.28696. Epub 2014 Apr 4.

Patient-derived xenografts for individualized care in advanced sarcoma.

Author information

1
Department of Oncology, Imperial College and Imperial Healthcare National Health Service Trust, Hammersmith Hospital, London, United Kingdom.

Erratum in

  • Cancer. 2014 Nov 15;120(22):3588. Zacharoulis, Stergios [added].

Abstract

BACKGROUND:

Patients with advanced, metastatic sarcoma have a poor prognosis, and the overall benefit from the few standard-of-care therapeutics available is small. The rarity of this tumor, combined with the wide range of subtypes, leads to difficulties in conducting clinical trials. The authors previously reported the outcome of patients with a variety of common solid tumors who received treatment with drug regimens that were first tested in patient-derived xenografts using a proprietary method ("TumorGrafts").

METHODS:

Tumors resected from 29 patients with sarcoma were implanted into immunodeficient mice to identify drug targets and drugs for clinical use. The results of drug sensitivity testing in the TumorGrafts were used to personalize cancer treatment.

RESULTS:

Of 29 implanted tumors, 22 (76%) successfully engrafted, permitting the identification of treatment regimens for these patients. Although 6 patients died before the completion of TumorGraft testing, a correlation between TumorGraft results and clinical outcome was observed in 13 of 16 (81%) of the remaining individuals. No patients progressed during the TumorGraft-predicted therapy.

CONCLUSIONS:

The current data support the use of the personalized TumorGraft model as an investigational platform for therapeutic decision-making that can guide treatment for rare tumors such as sarcomas. A randomized phase 3 trial versus physician's choice is warranted.

KEYWORDS:

TumorGraft; biomarker; chemotherapy; mice; prediction; response; sarcoma; trial

PMID:
24705963
PMCID:
PMC4298787
DOI:
10.1002/cncr.28696
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center